Top

Published in:

Open Access 01-05-2009 | Clinical Trial

Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

Authors: T. Byrski, T. Huzarski, R. Dent, J. Gronwald, D. Zuziak, C. Cybulski, J. Kladny, B. Gorski, J. Lubinski, S. A. Narod

Published in: Breast Cancer Research and Treatment | Issue 2/2009

Abstract

Background Ten patients with breast cancer and a breast cancer susceptibility gene 1 (BRCA1) mutation, who presented with stages I to III breast cancer between December 2006 and 2007, were treated with four cycles of neoadjuvant cisplatin, followed by mastectomy and conventional chemotherapy. Methods The excised breast tissue and lymph nodes were examined for the presence of residual disease. Results Pathologic complete response was observed in nine patients (90%). Conclusions Platinum-based chemotherapy appears to be effective in a high proportion of patients with BRCA1-associated breast cancers. Clinical trials are now warranted to determine the optimum treatment for this subgroup of breast cancer patients.

Gralow JR, Burstein HJ, Wood W et al (2008) Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 26:814–819. doi:10.1200/JCO.2007.15.3510 PubMedCrossRef

Liedtke C, Mazouni C, Hess KR et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 10:1275–1281. doi:10.1200/JCO.2007.14.4147 CrossRef

Lakhani SR, Jacquemier J, Sloane JP et al (1998) Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90:1138–1145. doi:10.1093/jnci/90.15.1138 PubMedCrossRef

Foulkes WD, Metcalfe K, Sun P et al (2004) Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 10:2029–2034. doi:10.1158/1078-0432.CCR-03-1061 PubMedCrossRef

Tilanus-Linthorst MM, Obdeijn IM, Hop WC et al (2007) BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials. Clin Cancer Res 13:7357–7362. doi:10.1158/1078-0432.CCR-07-0689 PubMedCrossRef

Robson ME, Chappuis PO, Satagopan J et al (2004) A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 6:R8–R17. doi:10.1186/bcr658 PubMedCrossRef

Rennert G, Bisland-Naggan S, Barnett-Griness O et al (2007) Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357:115–123. doi:10.1056/NEJMoa070608 PubMedCrossRef

Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP (2004) The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 96:1659–1668PubMedCrossRef

Quinn JE, Kennedy RD, Mullan PB et al (2003) BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 6319:6221–6228

10.

Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK (2000) The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 275:23899–23903. doi:10.1074/jbc.C000276200 PubMedCrossRef

11.

Chabalier C, Lamare C, Racca C, Privat M, Valette A, Larminat F (2003) BRCA1 down-regulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 5:1001–1007

12.

Zhou C, Smith JL, Liu J (2003) Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1. Oncogene 22:2396–2404. doi:10.1038/sj.onc.1206319 PubMedCrossRef

13.

Shafee N, Smith CR, Wei S et al (2008) Cancer stem cells contribute to cisplatin resistance in BRCA1-p53-mediated mouse tumours. Cancer Res 68:3243–3250. doi:10.1158/0008-5472.CAN-07-5480 PubMedCrossRef

14.

Decatris MP, Sundar S, O’Byrne KJ (2004) Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer Treat Rev 4:53–81. doi:10.1016/S0305-7372(03)00139-7 CrossRef

15.

Górski B, Jakubowska A, Huzarski T et al (2004) A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer 110:683–686. doi:10.1002/ijc.20162 PubMedCrossRef

16.

NCI National Cancer Institute (2003) Common terminology criteria for adverse events (CTCAE), version 3, June 10, 2004 update. National Cancer Institute, National Institutes of Health, Bethesda, MD

17.

Richards MA, Smith IE, Dixon JM (1994) ABC of breast diseases. Role Syst Treat Prim Operable Breast Cancer BMJ 309:1363–1366

18.

Buzdar AU, Ibrahim NK, Francis D et al (2005) Significantly higher pathologic complete remission after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy. Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23:3676–3685. doi:10.1200/JCO.2005.07.032 PubMedCrossRef

19.

Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY (2003) Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97:2187–2195. doi:10.1002/cncr.11310 PubMedCrossRef

20.

Turner N, Tutt A, Ashworth A (2005) Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol 5:388–393. doi:10.1016/j.coph.2005.03.006 PubMedCrossRef

Title: Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
Authors: T. Byrski
T. Huzarski
R. Dent
J. Gronwald
D. Zuziak
C. Cybulski
J. Kladny
B. Gorski
J. Lubinski
S. A. Narod
Publication date: 01-05-2009
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-008-0128-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2009

Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose?

CYP2C19*17 is associated with decreased breast cancer risk

Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers

Pattern of metastatic spread in triple-negative breast cancer

Link between insulin and metabolic disorders in cancer: does leptin play a key role?

Systemic chemokine levels in breast cancer patients and their relationship with circulating menstrual hormones

Keynote webinar | Spotlight on antibody–drug conjugates in cancer